BANK VONTOBEL/CALL/NOVO NORDISK ADR B/125/0.1/21.06.24 | Delayed Deutsche Boerse AG 08:01:48 2024-05-08 EDT | ||
| 0.64 EUR | +4.92% |
|
| Current month | -29.89% | ||
| 1 month | -21.79% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 0.64 | +4.92% | 0 |
| 24-05-07 | 0.61 | +32.61% | 0 |
| 24-05-06 | 0.46 | 0.00% | 0 |
| 24-05-03 | 0.46 | -22.03% | 13,825 |
| 24-05-02 | 0.59 | -32.18% | 0 |
Delayed Quote Deutsche Boerse AG
Last update May 08, 2024 at 08:01 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VM31BM |
| ISIN | DE000VM31BM4 |
| Date issued | 2023-10-16 |
| Strike | 125 $ |
| Maturity | 2024-06-21 (44 Days) |
| Parity | 10 : 1 |
| Emission price | 0.52 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.62 € |
|---|---|
| Lowest since issue | 0.124 € |
| Spread | 0.01 € |
| Spread % | 1.61% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
882.6
DKK
Average target price
908.7
DKK
Spread / Average Target
+2.95%
- Stock Market
- Warrants
- Warrant